Pharma Focus Asia

Fujifilm Plans to Open Large Scale Cell Culture Production Site in USA

Introduction:

FUJIFILM Corporation plans to open a new large scale cell culture manufacturing site for biopharmaceuticals with an investment of more than US$ 2 billion. The new site will be located adjacent to the existing site in USA.

Features:

The new production facility will advance the growth of its biopharmaceutical Contract Development and Manufacturing business (CDMO). In addition, the investment made in this new site helps in fulfilling the unmet medical needs with the manufacturing of new drugs.

The new production facility will be situated adjacent to the existing site and offers commercial scale automated fill-finish and assembly,  packaging and labelling services other than drug manufacturing substances.

The facility offers 8 x 20,000L bioreactors to expand with the addition of 24 x 20,000L bioreactorsfor large-scale cell culture manufacturing.

The production facility is expected to start its operation in the spring of 2025.

Specifications:

NameFUJIFILM Corporation
TypeNew Construction
BudgetUS$2 billion
Year2025
magazine-slider-image
magazine-slider-image
Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024